Tandem Diabetes Care Maps Pharmacy Shift, Targets 65% Gross Margin and 2026 Mobi Tubeless Launch

Executives from Tandem Diabetes Care (NASDAQ: TNDM) outlined how a shift toward the pharmacy channel, an expanding product portfolio, and international buildout are expected to reshape the company's revenue mix and margin profile over the next several years during an investor discussion hosted by Oppenheimer medical device analyst Suraj Kalia. Pharmacy channel seen as near-term margin